Midatech taps Stephen Parker as its new chairman

10th Jun 2022 12:25

(Sharecast News) - Biotechnology company Midatech Pharma announced on Friday that its chairman and non-executive director Rolf Stahel intends to retire after its annual general meeting on 20 June.

The AIM-traded firm said it expected to appoint Dr Stephen Parker as its new non-executive chairman following the AGM.

It said Parker had more than 30 years of experience in leadership roles, both in the healthcare industry and in advisory roles.

Currently, he is chairman of Sareum Holdings and Drishti Discoveries, a non-executive Director of MGC Pharmaceuticals, and an Executive Director of sp2 Consulting.

Previously, Parker held a number of executive and board positions at various public and private biotech companies, as well as senior roles at "leading" investment banks.

The company said he has an MBA from City University, and a D.Phil. in biochemistry from Oxford University.

"On behalf of all stakeholders I would like to thank Rolf for his contribution to Midatech over the last seven years and, from a personal perspective, for his leadership and counsel during my tenure over the last two years," said chief executive and financial officer Stephen Stamp.

"I should also like to welcome Stephen to the board.

"Stephen's broad experience both as an executive in, and senior adviser to, the industry will be invaluable to Midatech in the next stage of the company's evolution."

At 1038 BST, shares in Midatech Pharma were up 1% at 10.10p.

Reporting by Josh White at Sharecast.com.